Induction-maintenance of Lopinavir/r in HIV-infected Subjects
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability and antiviral activity of a simplified
PI-based treatment regimen (Kaletra,ä) compared to conventional HAART regimens in patients
infected with HIV-1 who are on their first boosted-PI antiretroviral treatment regimen.
The potency of the antiviral activity of Kaletra has been clearly demonstrated in a wide
spectrum of patients in a number of different clinical trials.6-9 The durable viral
suppression seen after 4 years of therapy10 proves that it can provide effective, long-term
treatment for people with HIV-1.
Data from one of these trials (M97-720),6 an ongoing Phase II study of lopinavir/ritonavir in
combination with NRTIs suggests there may be a role for monoclass therapy with Kaletra in the
treatment of HIV-1-infection.